RxDoctor Payments Data

Brad Ginevan, MD

Family Medicine · Sheffield, ALNPI 1285732016

Payments from drug & device makers

$14,806in general payments, 2019–2025

Across 959 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$884
  • Amarin Pharma, Inc.$828
  • plus $7K from 52 others

What the payments were for

  • Food & beverage$14,69599%
  • Education$1121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk106$1,728
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC120$1,511
AbbVie(2 entities)142$1,401
AstraZeneca52$1,094
Lilly USA, LLC60$884
Amarin Pharma, Inc.46$828
Johnson & Johnson29$682
GSK39$607
Pfizer51$584
Merck28$576
Scilex Pharmaceuticals Inc.31$455
Boehringer Ingelheim18$347
Antares Pharma, Inc.20$329
Axsome Therapeutics, Inc.14$310
Phathom Pharmaceuticals, Inc.15$309
Takeda Pharmaceuticals U.S.A., Inc.21$302
Bayer14$258
Biohaven Pharmaceutical Holding Company Ltd.18$254
Medtronic18$248
Amgen(2 entities)15$228
Astellas Pharma US Inc5$173
Esperion Therapeutics, Inc.13$166
Eisai Inc.7$159
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$156
Jazz Pharmaceuticals Inc.6$117
Novartis7$117
Idorsia Pharmaceuticals US Inc3$115
Halozyme Inc4$76
Genentech USA, Inc.4$63
Sanofi-aventis U.S. LLC4$58
Tolmar, Inc.3$50
Collegium Pharmaceutical, Inc.3$47
Ironwood Pharmaceuticals, Inc3$47
Corcept Therapeutics2$43
Biohaven Pharmaceuticals, Inc.3$42
Abbott2$39
Mylan Specialty L.p.2$36
Avanir Pharmaceuticals, Inc.2$35
Sequel Med Tech, LLC1$29
Adlon Therapeutics L.p.2$28
Bausch Health US, LLC2$27
Dexcom, Inc.1$22
Optinose US, Inc.1$17
Otsuka America Pharmaceutical, Inc.1$17
Lundbeck LLC1$16
Supernus Pharmaceuticals, Inc.1$15
Vertex1$15
Insulet Corporation1$15
Bristol Myers Squibb1$15
Sumitomo Pharma America, Inc.1$14
Xeris Pharmaceuticals, Inc.1$14
Irhythm Technologies, Inc.1$14
E.r. Squibb & Sons, L.L.C.1$14
Athena Bioscience, LLC1$13
Alkermes, Inc.1$12
Daiichi Sankyo Inc.1$12
Biogen1$11
Kowa Pharmaceuticals America, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,806 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$284,820
Medicare patients
491
Services billed
8,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide231$258,573
OzempicSemaglutide162$167,941
Trelegy ElliptaFluticasone/Umeclidin/Vilanter209$152,127
JardianceEmpagliflozin195$137,811
EliquisApixaban162$126,745
TrulicityDulaglutide114$112,000
RelistorMethylnaltrexone Bromide47$108,938
FarxigaDapagliflozin Propanediol102$68,838
LinzessLinaclotide110$66,314
JanuviaSitagliptin Phosphate49$44,515
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,854$44,461
XareltoRivaroxaban53$37,762
KerendiaFinerenone51$36,419
RexultiBrexpiprazole16$22,665
MyrbetriqMirabegron39$21,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$884$370,572345 claims
Novo NordiskOzempic$1,728$167,941162 claims
GSKTrelegy Ellipta, Incruse Ellipta$607$160,672233 claims
Boehringer IngelheimJardiance$347$137,811195 claims
PfizerEliquis$584$126,745162 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,511$108,93847 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,094$93,280155 claims
AbbVieLinzess$1,401$66,314110 claims
MerckJanuvia$576$44,51549 claims
Johnson & JohnsonXarelto$682$37,76253 claims
BayerKerendia$258$36,41951 claims
Otsuka America Pharmaceutical, Inc.Rexulti$17$22,66516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Sheffield

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →